Revenue increased 442% and 188%, respectively, compared to the three and twelve month periods in the prior year driven by development efforts supporting Pharma clinical programs
TUCSON, Ariz., March 22, 2018 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM) (HTG), a provider of instruments, reagents and services for molecular profiling applications, today reported its financial results for the fourth quarter and year ended December 31, 2017.
Recent Accomplishments & Highlights:
- Achieved revenue of $7.9 million and $14.8 million for the three and twelve months ended December 31, 2017, respectively, which represents a 442% and 188% increase over the respective periods in 2016. Fourth quarter and full year 2017 revenue was driven primarily by the company’s collaborative development services programs.
- Completed underwritten public offering of 13,915,000 shares of its common stock at a price to the public of $2.90 per share, including 1,815,000 shares sold pursuant to the exercise in full of the underwriters’ option to purchase additional shares, in January 2018. The aggregate net proceeds from the offering were approximately $37.7 million, after deducting the underwriting discounts and commissions and offering expenses.
- Entered into a third statement of work for a new clinical assay development program under the company’s Master Assay Development, Commercialization and Manufacturing Agreement with QIAGEN Manchester Limited, (QML), a wholly owned subsidiary of QIAGEN, N.V. (NYSE:QGEN), in connection with a sponsor project agreement between QML and a pharmaceutical company, in January 2018.
- Entered into a new master collaboration agreement for translational programs with Merck KGaA, Darmstadt, Germany, in December 2017. The master collaboration agreement complements the previously announced master companion diagnostic agreement with Merck KGaA, and includes a statement of work with EMD Serono, the biopharmaceutical business of Merck KGaA, in the United States and Canada.
“We entered 2017 with specific goals to accelerate customer adoption, expand our BioPharma pipeline, initiate commercialization of our CE/IVD products in Europe and strengthen our balance sheet. 2017 exceeded our performance expectations, and we move into 2018 looking forward to continuing our momentum,” said TJ Johnson, President and CEO of HTG Molecular Diagnostics.
Fourth Quarter 2017 Financial Results:
Revenue for the fourth quarter of 2017 was $7.9 million, compared to $1.5 million for the fourth quarter of 2016. Net loss from operations for the fourth quarter of 2017 was $1.7 million, compared to $5.2 million for the fourth quarter of 2016.
Net loss for the fourth quarter of 2017 was $1.9 million, compared to $5.7 million for the fourth quarter of 2016. Net loss per share was $(0.15) for the fourth quarter of 2017 compared to $(0.76) for the fourth quarter of 2016.
Full Year 2017 Financial Results:
Revenue for the year ended December 31, 2017 was $14.8 million, compared to $5.1 million for the year ended December 31, 2016. Net loss from operations for the year ended December 31, 2017 was $17.7 million, compared to $24.3 million for year ended December 31, 2016.
Net loss for the year ended December 31, 2017 was $19.0 million, compared to $26.0 million for the year ended December 31, 2016. Net loss per share for the year ended December 31, 2017 was $(1.79) compared to $(3.66) for the year ended December 31, 2016.
HTG ended 2017 with $10.0 million in cash and equivalents and current liabilities of approximately $13.3 million plus an additional $11.0 million in non-current liabilities. Net proceeds from the underwritten public offering completed on January 23, 2018 were approximately $37.7 million, after deducting for underwriting discounts and commissions and offering expenses.
Conference Call and Webcast:
HTG will host an investment community conference call today beginning at 4:30 p.m. Eastern Time. Conference call and webcast details follow:
|Date:||Thursday, March 22|
|Time:||4:30pm Eastern Time|
|Toll Free:||(800) 239-9838|
HTG is focused on next generation sequencing (NGS) based molecular profiling. The company’s proprietary HTG EdgeSeq technology automates complex, highly multiplexed molecular profiling from solid and liquid samples, even when limited in amount. HTG’s customers use its technology to identify biomarkers important for precision medicine, to understand the clinical relevance of these discoveries, and ultimately to identify treatment options. Our mission is to empower precision medicine at the local level.
-Financial tables follow-
|HTG Molecular Diagnostics, Inc.|
|Statements of Operations|
|Three Months Ended December 31,||Years Ended December 31,|
|Product and product-related services||$||2,374,951||$||1,457,781||$||6,797,255||$||5,132,730|
|Collaborative development services||5,529,207||—||7,962,312||—|
|Cost of revenue||1,350,613||1,234,429||4,971,806||4,135,884|
|Selling, general and administrative||4,603,491||4,083,832||17,513,742||17,427,777|
|Research and development||3,632,256||1,384,503||9,996,627||7,900,311|
|Total operating expenses||8,235,747||5,468,335||27,510,369||25,328,088|
|Other expense, net||(237,895||)||(422,239||)||(1,234,488||)||(1,698,190||)|
|Net loss before income taxes||(1,920,097||)||(5,667,222||)||(18,957,096||)||(26,029,432||)|
|Provision for income taxes||1,898||5,859||2,921||10,118|
|Net loss per share, basic and diluted||$||(0.15||)||$||(0.76||)||$||(1.79||)||$||(3.66||)|
|Shares used in computing net loss per share, basic and diluted||12,979,143||7,488,842||10,597,318||7,113,075|
|HTG Molecular Diagnostics, Inc.|
|Cash and cash equivalents||$||9,968,600||$||7,507,659|
|Short-term investments available-for-sale, at fair value||—||4,304,901|
|Prepaid expenses and other||443,068||433,328|
|Total current assets||17,948,457||15,134,382|
|Deferred offering costs||2,953||49,630|
|Property and equipment, net||3,304,890||3,270,197|
|Liabilities and stockholders' deficit|
|Deferred revenue - current||665,882||335,659|
|NuvoGen obligation - current||496,442||604,751|
|Term loan payable - current, net of discount and debt issuance costs of $64,807 at December 31, 2017 and $0 at December 31, 2016||5,793,599||6,389,782|
|Other current liabilities||200,460||258,850|
|Total current liabilities||13,341,967||10,020,991|
|Term loan payable - non-current, net of discount and debt issuance costs of $0 at December 31, 2017 and $263,378 at December 31, 2016||—||5,389,137|
|NuvoGen obligation - non-current, net of discount||7,520,913||8,017,356|
|Convertible note, related party - net of debt issuance costs||2,960,760|
|Other non-current liabilities||492,197||619,587|
|Commitments and Contingencies|
|Total stockholders’ deficit||(3,059,537||)||(5,592,862||)|
|Total liabilities and stockholders' deficit||$||21,256,300||$||18,454,209|
LifeSci Advisors, LLC
Phone: (617) 775-5956
President / CEO
HTG Molecular Diagnostics
Phone: (520) 547-2827 x130
Source:HTG Molecular Diagnostics, Inc.